# A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease

> **NCT07647614** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Energenesis Biomedical Co., Ltd.** · enrollment: 105 (estimated)

## Conditions studied

- Parkinson's Disease (PD)

## Interventions

- **DRUG:** 60 milligrams of ENERGI-F705 Tablets
- **DRUG:** Placebo tablets
- **DRUG:** 120 milligrams of ENERGI-F705 Tablets

## Key facts

- **NCT ID:** NCT07647614
- **Lead sponsor:** Energenesis Biomedical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2030-01-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07647614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07647614, "A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07647614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*